v3.26.1
Segments - Schedule of Reporting by Segment (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Schedule of Reporting by Segment [Line Items]              
Revenues $ 26,955   $ 49,954   $ 58,546 $ 248,535  
Gross margin 11,658   24,235   28,303 178,654  
Operating expenses              
Depreciation and amortization 2,610   2,968   5,215 6,491  
Selling, general and administrative 364,891   265,395   842,466 525,019  
Research and development 506,723   80,061   1,173,128 170,329  
Total operating expenses 874,224   348,424   2,020,809 701,839  
Other expenses              
Interest expense (3,325)   (56,139)   (6,170) (111,093)  
Fair value adjustment   66,519   30,511  
Other income (loss), net 146,208   5,049   293,472 1,035  
Net income (719,683) $ (985,521) (308,760) $ (293,974) (1,705,204) (602,732)  
Assets of segment 9,176,362       9,176,362   $ 6,497,177
Operating Segment [Member]              
Schedule of Reporting by Segment [Line Items]              
Revenues 26,955   49,954   58,546 248,535  
Gross margin 11,658   24,235   28,303 178,654  
Operating expenses              
Depreciation and amortization 2,610   2,968   5,215 6,491  
Selling, general and administrative 364,891   265,395   842,466 525,021  
Research and development 506,723   80,061   1,173,128 170,329  
Total operating expenses 874,224   348,424   2,020,809 701,841  
Other expenses              
Interest expense (3,325)   (56,139)   (6,170) (111,093)  
Fair value adjustment   66,519   30,511  
Other income (loss), net 146,208   5,049   293,472 1,035  
Other expenses 142,883   15,429   287,302 79,547  
Net income (719,683)   (308,760)   (1,705,204) (602,734)  
Assets of segment 9,176,361   1,625,818   9,176,361 1,625,818  
Biotechnology [Member]              
Schedule of Reporting by Segment [Line Items]              
Revenues      
Gross margin      
Operating expenses              
Depreciation and amortization 2,610   2,968   5,215 6,491  
Selling, general and administrative 341,318   248,203   800,254 484,740  
Research and development 469,300   69,339   1,106,069 144,776  
Total operating expenses 813,228   320,510   1,911,538 636,007  
Other expenses              
Interest expense (3,325)   (56,139)   (6,170) (111,093)  
Fair value adjustment   66,519   30,511  
Other income (loss), net 146,208   5,049   293,472 1,035  
Other expenses 142,883   15,429   287,302 79,547  
Net income (670,345)   (305,081)   (1,624,236) (715,554)  
Assets of segment 9,174,180   1,625,477   9,174,180 1,625,477  
Pharmaceutical [Member]              
Schedule of Reporting by Segment [Line Items]              
Revenues 26,955   49,954   58,546 248,535  
Gross margin 11,658   24,235   28,303 178,654  
Operating expenses              
Depreciation and amortization        
Selling, general and administrative 23,573   17,192   42,212 40,281  
Research and development 37,423   10,722   67,059 25,553  
Total operating expenses 60,996   27,914   109,271 65,834  
Other expenses              
Interest expense            
Fair value adjustment            
Other income (loss), net            
Other expenses      
Net income (49,338)   (3,679)   (80,968) 112,820  
Assets of segment $ 2,181   $ 341   $ 2,181 $ 341